SPI Infoamtion

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Breast Cancer Market: Market Characterization
2.1 Overview
2.2 Breast Cancer Market Size
2.3 Breast Cancer Market Forecast and CAGR
2.4 Drivers and Barriers for the Breast Cancer Market
2.4.1 Drivers for the Breast Cancer Market
2.4.2 Barriers for the Breast Cancer Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 Breast Cancer Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profiles of the Major Marketed Products in the Breast Cancer Market
3.3.1 Avastin (bevacizumab) + Paclitaxel
3.3.2 Arimidex (anastrozole)
3.3.3 Femara (letrozole)
3.3.4 Herceptin (trastuzumab)
3.3.5 Taxotere (docetaxel)
3.4 Key Takeaway

4 Breast Cancer Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Breast Cancer Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Afinitor
4.4.2 BSI-201
4.4.3 NeuVax
4.4.4 Stimuvax
4.4.5 Custirsen Sodium (OGX-011)
4.5 Breast Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action
4.6 Breast Cancer Pipeline – Pipeline by Clinical Phases of Development
4.6.1 Breast Cancer Therapeutics – Phase III Clinical Pipeline
4.6.2 Breast Cancer Therapeutics – Phase II Clinical Pipeline
4.6.3 Breast Cancer Therapeutics – Phase I Clinical Pipeline
4.6.4 Breast Cancer Therapeutics – Preclinical Pipeline
4.6.5 Discontinued / Suspended Drugs for Breast Cancer
4.7 Key Takeaway

5 Breast Cancer Market: Implications for Future Market Competition

6 Breast Cancer Market: Future Players in the Breast Cancer Market
6.1 Introduction
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Oncology Portfolio
6.2.3 Breast Cancer Portfolio
6.3 Oncogenex
6.3.1 Overview
6.3.2 Oncology Portfolio
6.3.3 Breast Cancer Product Portfolio
6.4 Apthera Inc
6.4.1 Overview
6.4.2 Oncology Portfolio
6.4.3 Breast Cancer Product Portfolio
6.5 BioNumerik Pharmaceuticals
6.5.1 Overview
6.5.2 Oncology Portfolio
6.6 Oncothyreon Inc
6.6.1 Overview
6.6.2 Oncology Portfolio
6.6.3 Breast Cancer Product Portfolio
6.7 Bipar Sciences
6.7.1 Overview
6.7.2 Oncology Portfolio
6.7.3 Breast Cancer Product Portfolio

7 Breast Cancer Market: Appendix
7.1 Market Definition
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panels
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Figures
Figure 1: Global Breast Cancer Market Forecast, 2001–2009
Figure 2: Global Breast Cancer Market Forecast, 2009–2016
Figure 3: Opportunity and Unmet Need in the Breast Cancer Market, 2010
Figure 4: Strategic Competitor Assessment of the Marketed Products for Breast Cancer, 2010
Figure 5: Technology Trends Analytic Framework of the Breast Cancer Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Breast Cancer Pipeline – Description, 2010
Figure 7: Breast Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Breast Cancer Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in the Breast Cancer Market, 2010
Figure 10: Breast Cancer Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Methodology
Figure 12: GlobalData Market Forecasting Model

List of Tables
Table 1: Global Breast Cancer Market Forecast, 2001–2009
Table 2: Global Breast Cancer Market Forecast, 2009–2016
Table 3: Marketed Product Analysis in the Breast Cancer Market, 2010
Table 4: Breast Cancer Therapeutics – Most Promising Drugs under Clinical Development, 2010
Table 5: Breast Cancer Pipeline, Combinations, Phase III, 2010
Table 6: Breast Cancer Pipeline, Monotherapy, Phase III, 2010
Table 7: Breast Cancer Pipeline, Combinations, Phase II, 2010
Table 8: Breast Cancer Pipeline, Monotherapy, Phase II, 2010
Table 9: Breast Cancer Pipeline, Combinations, Phase I, 2010
Table 10: Breast Cancer Pipeline, Monotherapy, Phase I, 2010
Table 11: Breast Cancer Pipeline, Pre-clinical and Discovery Phase, 2010
Table 12: List of Discontinued Drugs for Breast Cancer, 2010
Table 13: Novartis – Oncology Pipeline, 2010
Table 14: OncoGeneX – Oncology Pipeline, 2010
Table 15: Apthera Inc – Oncology Pipeline, 2010
Table 16: BioNumerik Pharmaceuticals, Inc. – Oncology Pipeline, 2010
Table 17: Oncothyreon Inc – Oncology Pipeline, 2010
Table 18: BiPar Sciences – Oncology Pipeline, 2010